We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Using PET Scans to Study Brain Receptor Occupancy of BIIB014 in Healthy Male Volunteers

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00531193
First Posted: September 18, 2007
Last Update Posted: July 30, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Biogen
  Purpose
To establish the extent to which BIIB014, following 8 to 12 consecutive days of dosing at selected dose levels, occupies the brain's A2A receptors. Receptor occupancy will be assessed by PET scanning using a radiolabelled tracer.

Condition Intervention Phase
Healthy Drug: BIIB014 Other: [11C]SCH442416 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of BIIB014 at Multiple Dose Levels in Healthy Male Volunteers

Resource links provided by NLM:


Further study details as provided by Biogen:

Primary Outcome Measures:
  • PET scanning with [11C]SCH442416 of the putamen, caudate, nucleus accumbens, thalamus, and cerebellum. [ Time Frame: pre-dose and 24h following last dose ]

Secondary Outcome Measures:
  • Concentrations of BIIB014 and its N-acetyl metabolite will be measured in blood plasma [ Time Frame: up to 24h following last dose ]

Enrollment: 32
Study Start Date: September 2007
Study Completion Date: April 2008
Primary Completion Date: April 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1
Various protocol-specified doses of BIIB014 will be used (doses to be determined by PET scan results)
Drug: BIIB014
oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
Other: [11C]SCH442416
11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.

Detailed Description:

Subjects will be enrolled sequentially into cohorts of 2 to 4 subjects. PET scan results will determine the actual number of cohorts enrolled and the BIIB014 dose given to each subject. Since all enrolled subjects will be receiving BIIB014, this study is being listed as a 1-arm, Single Group study (actual study design is dose escalation).

Participating subjects will be required to reside in the clinical unit for 10 to 14 consecutive days. Participants will receive 1 oral dose of BIIB014 daily for 8 to 12 consecutive days. During the study, subjects will undergo 2 PET scans and 1 MRI. Frequent blood sample for pharmacokinetic assessments will also be performed.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   25 Years to 55 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI between 18.0 and 29.0 kg/m2
  • Willing to abstain from caffeine-containing products from 1 week prior to dosing until discharge from unit.
  • Willing and able to practice effective contraception until 2 months following last dose of study drug.

Exclusion Criteria:

  • History of severe allergic reactions or clinically significant allergies.
  • History of malignancy, excluding adequately treated basal cell carcinoma.
  • History of any clinically significant disease.
  • History of claustrophobia or any condition incompatible with MRI/PET scanning.
  • History of any exposure to ionizing radiation, with the exception of dental x-rays, within the 12 months prior to dosing.
  • Serious infection within the 4 weeks prior to dosing.
  • HbA1c > 6%, positive for Hepatitis C or Hepatitis B, presence of HIV or known exposure to HIV, positive G6PD assay, or any other clinically significant abnormal laboratory parameters at Screening.
  • Abnormal supine or standing blood pressure or orthostatic hypotension.
  • Any prior treatment with antipsychotic medications, dopamine antagonists, or dopaminergic agonists.
  • Treatment with any other investigational drug within 3 months prior to dosing.
  • Treatment with any prescription medications within 4 weeks prior to dosing.
  • History of drug or alcohol abuse within 1 year prior to dosing.
  • Current smoker or any tobacco use within 3 months prior to dosing.
  • Heavy caffeine consumption within 4 weeks prior to dosing.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00531193


Locations
United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Biogen
Investigators
Study Director: Biogen Idec Cambridge, MA USA
  More Information

Responsible Party: Biogen Idec MD, Biogen Idec
ClinicalTrials.gov Identifier: NCT00531193     History of Changes
Other Study ID Numbers: 204HV101
EUDRACT 2007-001575-10
First Submitted: September 17, 2007
First Posted: September 18, 2007
Last Update Posted: July 30, 2008
Last Verified: July 2008

Keywords provided by Biogen:
Healthy male volunteers

Additional relevant MeSH terms:
Adenosine
3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Vasodilator Agents
Purinergic P1 Receptor Agonists
Purinergic Agonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adenosine A2 Receptor Antagonists
Purinergic P1 Receptor Antagonists
Purinergic Antagonists